Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in XXXX @entity1 . A systematic review of the literature with meta-analysis.

@entity1 @entity137 @entity1261 @entity5 @entity221 @entity1398 @entity2841
The effectiveness of granulocyte and @entity1261 and @entity2841 ) in the treatment of @entity5 @entity1 remains controversial. To assess their role in this condition, we conducted a systematic review of randomised trials published as full papers. A methodological evaluation using a specifically designed quality scale was performed before meta-analysis. Eleven trials were eligible, 8 of which were meta-analysable. The median quality score for the 11 pooled trials was 58.3% (range: 33.3%-68.8%). No significant quality difference was observed between positive (colony-stimulating factor more effective) and negative trials ( P=0.36). No quality difference was observed between the 8 meta-analysable studies and the 3 others, with respective median scores of 59.3% and 50%. No advantage was detected for the use of CSF in terms of mortality from @entity1398 , with a relative risk of 0.71 (95% CI 0.44-1.15). The relative risk was 0.66 (95% CI 0.39-1.13) in the @entity1261 subgroup and 0.97 (95% CI 0.34-2.79) in the @entity2841 subgroup. Aggregation of the results on infection-related mortality, length of stay in hospital, @entity221 and of @entity1398 duration, antibiotic therapy adaptation and duration, superinfection rate and @entity137 was not possible owing to the lack of adequate data in the publications. On the basis of this review, we cannot recommend the routine use of @entity1261 or @entity2841 in established @entity1398 .
